At the time of writing, Macrogenics Inc [MGNX] stock is trading at $3.60, down -0.55%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MGNX shares have gain 7.78% over the last week, with a monthly amount drifted -32.46%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Macrogenics Inc [NASDAQ: MGNX] stock has seen the most recent analyst activity on August 01, 2024, when BTIG Research downgraded its rating to a Neutral. Previously, Guggenheim downgraded its rating to Neutral on July 31, 2024. On July 31, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $5 on the stock. TD Cowen downgraded its rating to a Hold. Stifel downgraded its rating to a Hold and reduced its price target to $7 on May 10, 2024. BMO Capital Markets downgraded its rating to Market Perform for this stock on May 10, 2024, and downed its price target to $8. In a note dated April 26, 2024, B. Riley Securities initiated an Buy rating and provided a target price of $25 on this stock.
For the past year, the stock price of Macrogenics Inc fluctuated between $3.14 and $21.88. Currently, Wall Street analysts expect the stock to reach $10.33 within the next 12 months. Macrogenics Inc [NASDAQ: MGNX] shares were valued at $3.60 at the most recent close of the market. An investor can expect a potential return of 186.94% based on the average MGNX price forecast.
Analyzing the MGNX fundamentals
According to Macrogenics Inc [NASDAQ:MGNX], the company’s sales were 41.02M for trailing twelve months, which represents an -17.81% plunge. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -4.8%, Pretax Profit Margin comes in at -3.32%, and Net Profit Margin reading is -3.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.68, Equity is -1.07 and Total Capital is -1.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.52 points at the first support level, and at 3.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.69, and for the 2nd resistance point, it is at 3.78.
Ratios To Look Out For
It is important to note that Macrogenics Inc [NASDAQ:MGNX] has a current ratio of 2.71. Further, the Quick Ratio stands at 2.69, while the Cash Ratio is 1.45. Considering the valuation of this stock, the price to sales ratio is 5.50, the price to book ratio is 3.91.
Transactions by insiders
Recent insider trading involved Peters Jeffrey Stuart, Senior VP and General Counsel, that happened on Apr 04 ’24 when 51395.0 shares were sold. Senior VP and General Counsel, Peters Jeffrey Stuart completed a deal on Mar 06 ’24 to sell 19625.0 shares. Meanwhile, Chief Operating Officer Risser Eric Blasius sold 41159.0 shares on Mar 04 ’24.
